Accueil   Diary - News   All news VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions
of the American Diabetes Association

 

  • TOTUM-63 reduces inflammation in visceral adipose tissue, one of the mechanisms leading to type 2 diabetes and metabolic diseases.
  • The efficacy of TOTUM-63 on sugar and lipid metabolism is confirmed in a murine model of prediabetes.
  • These results were obtained by an independent study led by Dr. Bruno GUIGAS at Leiden University (Netherlands).

 

La Rochelle, 7 June 2019 (7:35 CEST) – VALBIOTIS FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced that new preclinical results of TOTUM-63 obtained independently by Leiden University (Netherlands) will be presented at the 2019 scientific sessions of the American Diabetes Association, being held from June 7 to 11 in San Francisco, California. In a murine model of prediabetes, TOTUM-63 reduced inflammation in visceral adipose tissue, one of the pathophysiological mechanisms of metabolic diseases, especially type 2 diabetes. Moreover, this study also confirmed the efficacy of TOTUM-63 on sugar and lipid metabolism in this preclinical model.

Read the press release